

# Marzena Laskowska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8427110/publications.pdf>

Version: 2024-02-01

31  
papers

425  
citations

759233

12  
h-index

752698

20  
g-index

34  
all docs

34  
docs citations

34  
times ranked

598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lead Levels in Non-Occupationally Exposed Women with Preeclampsia. <i>Molecules</i> , 2021, 26, 3051.	3.8	6
2	Urinary iodine as an important indicator for preeclampsia: a Polish perspective. <i>Current Issues in Pharmacy and Medical Sciences</i> , 2021, .	0.4	0
3	Chemical elements and preeclampsia - An overview of current problems, challenges and significance of recent research. <i>Journal of Trace Elements in Medicine and Biology</i> , 2020, 59, 126468.	3.0	12
4	Badania mikrobiologiczne u kobiet ciążarnych – standardy postępowania. <i>Forum Zakaznicze</i> , 2020, 11, 100-110.	0	0
5	Eclampsia – emergency condition in obstetrics: case reports of two patients. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 1171-1172.	0.9	0
6	The Role of Nitric Oxide, ADMA, and Homocysteine in The Etiopathogenesis of Preeclampsia – Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2757.	4.1	37
7	The influence of nebivolol on the activity of BRL 37344 – the $\beta_2$ adrenergic receptor agonist, in the animal model of detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2019, 38, 1229-1240.	1.5	3
8	Angiogenic Imbalance as a Contributor of Preeclampsia. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 797-815.	1.6	21
9	Preeclampsia - Current Management and Future Approach. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 786-796.	1.6	36
10	Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia. <i>BioMed Research International</i> , 2017, 2017, 1-9.	1.9	40
11	The relation of maternal serum eNOS, NOSTRIN and ADMA levels with aetiopathogenesis of preeclampsia and/or intrauterine fetal growth restriction. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 26-32.	1.5	18
12	Differences in the Association between Maternal Serum Homocysteine and ADMA Levels in Women with Pregnancies Complicated by Preeclampsia and/or Intrauterine Growth Restriction. <i>Hypertension in Pregnancy</i> , 2013, 32, 83-93.	1.1	11
13	Elevated maternal serum sP-selectin levels in preeclamptic pregnancies with and without intrauterine fetal growth restriction, but not in normotensive pregnancies complicated by isolated IUGR. <i>Medical Science Monitor</i> , 2013, 19, 118-124.	1.1	12
14	A comparison of maternal serum levels of endothelial nitric oxide synthase, asymmetric dimethylarginine, and homocysteine in normal and preeclamptic pregnancies. <i>Medical Science Monitor</i> , 2013, 19, 430-437.	1.1	31
15	Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 806-811.	1.5	8
16	Maternal soluble human leukocyte antigen-G levels in pregnancies complicated by foetal intrauterine growth restriction with and without preeclampsia. <i>Pregnancy Hypertension</i> , 2012, 2, 168-173.	1.4	1
17	Asymmetric dimethylarginine in normotensive pregnant women with isolated fetal intrauterine growth restriction: a comparison with preeclamptic women with and without intrauterine growth restriction. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2011, 24, 936-942.	1.5	14
18	Interleukin-18 concentrations in pregnancies complicated by preeclampsia with and without IUGR: A comparison with normotensive pregnant women with isolated IUGR and healthy pregnant women. <i>Pregnancy Hypertension</i> , 2011, 1, 206-212.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Umbilical sP-selectin levels are different in preeclamptic pregnancies with intrauterine normal growth and growth restricted fetus. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2011, 24, 795-798.	1.5	0
20	Evaluation of sCD30 level in maternal serum in pregnancies complicated by severe preeclampsia. , 2011, 15, 73-8.		0
21	Soluble CD30 in normotensive pregnant women with isolated fetal intrauterine growth restriction: a comparison with preeclamptic women. <i>Journal of Reproductive Immunology</i> , 2010, 86, 122-125.	1.9	2
22	Are the maternal and umbilical VEGF-A and SVEGF-R1 altered in pregnancies complicated by preeclampsia with or without intrauterine foetal growth retardation? Preliminary communication. , 2008, 12, 499-506.		3
23	Maternal and Umbilical sTNF-R1 in Preeclamptic Pregnancies with Intrauterine Normal and Growth Retarded Fetus. <i>Hypertension in Pregnancy</i> , 2007, 26, 13-21.	1.1	17
24	sCD40 Ligand Determined in Maternal and Umbilical Cord Blood in Pregnancies Complicated by Pre-Eclampsia with and without Intrauterine Growth Retardation. <i>Gynecologic and Obstetric Investigation</i> , 2007, 64, 8-13.	1.6	13
25	Comparative analysis of the maternal and umbilical interleukin-8 levels in normal pregnancies and in pregnancies complicated by preeclampsia with intrauterine normal growth and intrauterine growth retardation. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2007, 20, 527-532.	1.5	40
26	Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 126, 155-159.	1.1	10
27	Evaluation of maternal and umbilical serum TNF $\alpha$ levels in preeclamptic pregnancies in the intrauterine normal and growth-restricted fetus. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2006, 19, 347-351.	1.5	36
28	Maternal and umbilical soluble Fas concentration in normotensive and preeclamptic pregnancies. <i>International Journal of Gynecology and Obstetrics</i> , 2005, 89, 45-46.	2.3	4
29	Placental angiotensin II receptor AT1R in normotensive patients and its correlation between infant birth weight. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2003, 109, 166-170.	1.1	10
30	Comparative Analysis of the Angiotensin-II Receptor in Placental Vascular Endothelial Cells in Preeclamptic and Normotensive Patients. <i>Gynecologic and Obstetric Investigation</i> , 2003, 56, 55-60.	1.6	8
31	Pregnancy in Women with Epilepsy. <i>Gynecologic and Obstetric Investigation</i> , 2001, 51, 99-102.	1.6	27